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ABSTRACT 
Atherosclerosis is the early stage of arterial 
disease, and underlies development of cardio- 
vascular disease (CVD) and stroke. Although 
sophisticated models for assessing CVD and 
stroke risk have been derived based on large- 
scale prospective studies, their abilities in detect- 
ing the presence or absence of atherosclerotic 
plaque have not been investigated. This study 
aimed to evaluate and compare discriminatory 
and risk stratifying abilities of 13 CVD risk as- 
sessment models against the ultrasound detec- 
tion of carotid plaques in type 2 diabetes melli- 
tus (T2DM) patients. Forty-nine T2DM subjects 
were recruited with informed consent, and major 
anthropomorphic and biomarker data for these 
models were collected. The model risk scores 
were evaluated against the carotid plaques de- 
tected by Doppler ultrasound. Only the FHS- 
Lpts-CHD-10Y model, which is a variant of the 
Framingham model, revealed an area under the 
receiver operating curve (AUROC) that was sig- 
nificantly different from a random scoring ap- 
proach (AUROC: 0.681, p < 0.05), and was able 
to stratify the risk levels of carotid plaque pre- 
sence (Chi-Square statistic: 5.99, p < 0.05). 
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1. INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is an increasingly 
common and severe problem worldwide. The major cause 
of death in T2DM patients is cardiovascular disease 
(CVD), and the relationship between T2DM and CVD is 
so strong that T2DM is regarded as a “risk equivalent” to 
a previous coronary event. Thus, T2DM patients are re- 
cognized to be high risk subjects. The underlying cause 
of CVD is atherosclerosis in coronary and carotid arter- 
ies. There are many factors apart from diabetes that are 
associated with accelerated atherosclerosis and elevated 
risk of CVD. These include hypertension, inflammation, 
obesity and dyslipidemia [1,2]. 
The development of atherosclerosis is silent but can be 
accelerated by the combined influence of multiple risk 
factors [1,2]. The American Heart Association (AHA) 
reported that no previous symptoms were observed in 
50% of men and 64% of women who died suddenly of 
coronary heart disease (CHD) [3]. Therefore, there is a 
need to screen asymptomatic individuals for the purposes 
of CVD risk assessment. An ideal risk assessment model 
would be simple, non-invasive and use inexpensive tools 
to identify those with high CVD risk prior to develop- 
ment of symptoms. Such a model would enable early 
intervention for delay or prevention of clinical endpoints 
such as acute myocardial Infarction (MI) and stroke [4]. 
Many statistical models for assessing CVD risk have 
been developed based on the findings of large epidemic- 
ological studies. These are derived mainly from the 
Atherosclerosis Risk in Communities (ARIC), the Fra- 
mingham Heart Study (FHS) and the United Kingdom 
Prospective Diabetes Study (UKPDS) [5-7]. Atheroscle- 
rosis is the early stage of CVD. The important morpho- 
logical changes in atherosclerotic burden over time, such 
as the carotid intimal-medial thickness and carotid plaque 
presence, can be assessed by Doppler and B-mode ca- 
rotid ultrasound. The morphological changes can be used 
in conjunction with or incorporated into any of the cur- 
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rently used CVD risk assessment models. Wyman et al. 
reviewed the literature to determine the association be- 
tween carotid plaque presence and future CVD events 
and found that, in nine studies with over 38,000 subjects 
in total investigated, ultrasound-detected carotid plaque 
could predict future CVD to a significant extent [4]. 
Though the Adult Treatment Panel III (NCEP-ATP III) 
suggested that the finding of advanced sub-clinical 
atherosclerosis obtained by noninvasive testing can help 
confirm the high CVD risk in older persons, the use of 
risk assessment models is still indispensable to screening 
of individuals [8]. 
This paper focuses on thirteen CVD risk assessment 
models derived from these three well-renowned studies, 
which were all performed in Western populations. For 
simplicity, short forms are used to represent the models 
in this paper and the descriptions are shown in Table 1. 
The risk factors considered for these thirteen CVD risk 
assessment models are summarized in Table 2. 
Atherosclerosis and CVD have common risk factors. 
Therefore, we hypothesize that the classical risk models 
can be transformed to detect the plaque presence in the 
carotid artery. In the evaluation and adjustment of CVD 
models, the generated CVD risk scores should be com- 
pared or calibrated against actual presence or absence of 
plaque. 
 
Table 1. Short forms and descriptions of thirteen CVD risk 
assessment models. 
CVD Risk Model Description 
(1) ARIC-Black-CHD-10Y ARIC 10-year risk of coronary heartdisease in black people 
(2) ARIC-White-CHD-10Y ARIC 10-year risk of coronary heartdisease in white people 
(3) ARIC-Black-Stroke-10Y ARIC 10-year risk of stroke in black people 
(4) ARIC-White-Stroke-10Y ARIC 10-year risk of stroke in  white people 
(5) FHS-HCHD-10Y FHS 10-year risk of hard coronary heart disease 
(6) FHS-Lpts-CHD-10Y FHS 10-year risk of coronary heart disease using LDL-C points 
(7) FHS-Cpts-CHD-10Y FHS 10-year risk of coronary heart disease using Total-C points 
(8) FHS-CHD-2Y FHS 2-year risk of coronary heart disease 
(9) FHS-Stroke-10Y FHS 10-year risk of stroke 
(10) UKPDS-CHD-10Y UKPDS 10-year risk of coronary heart disease 
(11) UKPDS-Fatal-CHD-10Y UKPDS 10-year risk of fatal  coronary heart disease 
(12) UKPDS-Stroke-10Y UKPDS 10-year risk of stroke 
(13) UKPDS-Fatal-Stroke-10Y UKPDS 10-year risk of fatal stroke
Further, some previous studies have validated the use 
of risk assessment models for the Western population 
from which they were constructed [5,9-11]. These mod- 
els may not be directly applicable to Asian populations 
who do not share all the same CVD risk characteristics 
with Western populations, and they tend to over-estimate 
the CVD risk in the Asian populations [12]. The per- 
formance of the Framingham CHD risk assessment tool 
applied to Chinese participants recruited from 11 prov- 
inces in China was evaluated in the Chinese Multi-pro- 
vincial Cohort Study (CMCS) [10]. It was found that the 
tool developed based on the data collected from white 
US participants also over-estimated the absolute CHD 
risk in the CMCS cohort, and recalibration of the Fram- 
ingham functions improved the performance [10]. Sex- 
specific optimal 10-year risk prediction models were 
developed based on 17-year follow-up data from the 
USA-PRC Collaborative Study of Cardiovascular Epi-
demiology cohort to better the estimation of the CVD 
risk in Chinese population [13]. However, these previous 
studies did not focus on the early detection of carotid 
plaques, through which the proactive risk assessment and 
prevention of CVD can be achieved. There is a lack of 
the evaluation of cardiovascular risk models in the Hong 
Kong population where a large number of people are 
exposed to a major CVD risk factor, T2DM. Diabetes 
Hong Kong reported that the diabetic population in Hong 
Kong was 10% of the total population, with diabetes 
cases reaching almost 700,000 in 2008. In line with the 
global situation, there is a surging trend of diabetes lo- 
cally. Therefore, it is meaningful to investigate the ultra- 
sound-guided approach for evaluation of CVD risk as- 
sessment models in high risk groups and for use with 
other population groups, so as to provide an economical 
way to identify individuals who would benefit from early 
intervention. In this regard, a preliminary study was per- 
formed on 32 Hong Kong Chinese people and the per- 
formances of three risk models were compared though 
the sample size was not large enough to achieve a high 
level of statistical power [14]. 
1.1. CVD Risk Assessment Models versus 
Detection of Carotid Plaque 
The findings of ARIC, FHS, UKPDS have been wide- 
ly discussed in the literature. The assessment models de- 
veloped based on their findings have been packaged into 
various kinds of tools, such as web-based risk engines, 
downloadable software applications and lookup tables in 
spreadsheets, which allow free access by the public. As 
these models attempt to predict CVD risk based on the 
levels of selected risk factors, the effect on an individ- 
ual’s CVD risk can be assessed by modulating or ma- 
nipulating some risk factors. This ‘simulating’ feature is 
particularly useful for suggesting intervention focusing 
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Table 2. Risk factors considered for the risk assessment models in ARIC, FHS and UKPDS. 
ARIC: (1)-(4) FHS: (5)-(9) UKPDS: (10)-(13) 
Risk Factors (1) Black 
CHD 
10Y 
(2) 
White 
CHD 
10Y 
(3) 
Black 
Stroke 
10Y 
(4) 
White 
Stroke 
10Y 
(5) 
HCHD 
10Y 
(6) 
Lpts 
CHD 
10Y
(7) 
Cpts CHD 
10Y 
(8) 
CHD 2Y
(9) 
Stroke 
10Y 
(10) 
CHD 10Y 
(11) 
Fatal CHD 
10Y 
(12) 
Stroke 
10Y 
(13) 
Fatal 
Stroke 
10Y 
Age * * * * * * * * *     
Age at Diagnosis 
of T 2DM          * * * *
Duration of T2DM          * * * *
BMI          * * * *
Sex * * * * * * * * * * * * *
Ethnicity ┼ ┼ ┼ ┼      ┼ ┼ ┼ ┼ 
Smoking ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ 
Alcohol        *      
Menopause if 
female        ┼      
Antihypertensive 
Medication * * * *    * *     
Total-C * *   *  *   * * * *
HDL-C * *   * * * *  * * * *
LDL-C      *        
HbA1c          * * * *
SBP * * * * * * * * * * * * *
DBP      * *       
Diabetes ○ ○ ○ ○  ○ ○ ○ ○     
Atrial Fibrillation         ┼ ┼ ┼ ┼ ┼ 
CVD         ○     
LVH   ┼ ┼     ┼     
CHD   ○ ○          
Lpts: LDL points; Cpts: Cholesterol points; HCHD: hard coronary heart disease; BMI: body mass index; Total-C: total cholesterol; HDL-C: high-density lipo-
protein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: haemoglobin A1c; CVD: 
cardiovascular disease; LVH: left ventricular hypertrophy; CHD: coronary heart disease;. *Risk factor having data; ○Risk factor based on the selection criteria 
(Smoking: no; Diabetes: yes; CVD: no; CHD: no); ┼Risk factor fixed by assumption (Ethnicity: white; Menopause: no; Atrial Fibrillation: no; LVH: no). 
 
on some modifiable risk factors that could reduce CVD 
risk most significantly or cost-effectively. 
The CVD risk predicted by these models is normally 
in the two-year or ten-year basis, which is conceptually 
too ambiguous for the health practitioners to gain insight 
into the relationship between calculated risk and current 
atherosclerotic plaque formation. Increased likelihood of 
severe carotid atherosclerosis was observed in persons 
with diabetes, and diabetic patients suffer from irreversi- 
ble brain damage due to carotid emboli more commonly 
than non-diabetic subjects [15,16]. Though many exist- 
ing studies have investigated the link between athero- 
sclerosis and CVD, no study to date has validated the 
ability of CVD risk assessment models in predicting the 
presence of atherosclerotic plaques [4,17,18]. 
Ultrasound screening is a commonly used tool to de- 
tect plaque in the carotid arteries. In routine clinical prac- 
tice, many physicians request carotid ultrasound exami- 
nations even for patients with no obvious elevation of 
CVD risk [18]. Though the screening for carotid plaque 
does not require advanced training and the scanning time 
is much shorter than measurement of Carotid Intimal 
Medial Thickness (CIMT), the cost for a screening ses- 
sion and image reporting is still very high compared with 
that of using other risk assessment models [4]. Therefore, 
models with the ability to identify the presence or ab-
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sence of carotid plaques would be useful and cost-effec- 
tive primary clinical tools that would enhance the reli- 
ability and currency of CVD risk assessment. Plaque- 
sensitive risk assessment models would be very mean- 
ingful to the care of diabetic patients, who normally do 
not undergo periodic carotid ultrasound examinations. 
1.2. Research Question and Objectives 
The research question is: “Do the CVD risk assess- 
ment models derived from FHS, UKPDS and ARIC 
studies predict carotid plaque presence in the population 
of interest (T2DM patients in Hong Kong)?”. To address 
this question, this study had two aims: the primary aim 
was to evaluate and compare the discriminatory ability of 
the risk assessment models derived from FHS, UKPDS 
and ARIC in classifying T2DM patients as likely to be 
positive (high risk) or negative (low risk) for carotid 
plaque; the second aim was to verify the agreement be- 
tween the likelihood of the predicted CVD and that of 
the actual carotid plaque presence at different assessed 
risk levels in the model found to have the best discrimi- 
natory ability. 
2. METHODS 
2.1. Subjects and Sample Size 
This study was approved by the Human Subjects Eth-
ics Sub-Committee of the Hong Kong Polytechnic Uni- 
versity (PolyU), and subjects gave their written informed 
consent. Inclusion criteria were: T2DM patient, aged 46 
to 60 years, non-smoker; no record of stroke or coronary 
heart disease. Forty-nine subjects (35 females and 14 
males) were recruited and all were Hong Kong Chinese. 
The mean and standard deviation of age were 54 and 
4.55 years. In the power analysis, we chose significance 
level (α) of 0.05, statistical power of 0.9 and effect size 
of 0.5 (a medium difference) and estimated the required 
sample size as 44. As the dataset was used for evaluating 
but not developing the risk assessment models, a very 
large sample was not required. 
2.2. Measurement and Data Collection 
Each subject completed a questionnaire, which col- 
lected information including age, gender, occupation, du- 
ration of T2DM, self and family history of diseases, an- 
tihypertensive medication, diet, alcohol, sleeping habits 
(sleep quality and quantity) and physical exercise. 
Fasting was required for 8 - 12 hours before blood and 
urine sample collection. A panel of biomarkers reflecting 
risk of vascular disease in these subjects was measured, 
including complete blood count (CBC), plasma glucose, 
LDL-C, HDL-C and Total-C for lipid profile, high sensi- 
tivity C-reactive protein (hs-CRP), uric acid, the total 
antioxidant capacity as the ferric reducing antioxidant 
power (FRAP) value, and ascorbic acid (AA). 
Anthropologic parameters, such as height, weight and 
waistline, were measured. After 5-minute resting, SBP 
and DBP were measured using a blood pressure monitor, 
Welch Allyn Atlas Monitor 62,000 Series. 
B-mode and color flow Doppler ultrasound was used 
to interrogate the carotid arteries of subjects and identify 
the presence of carotid plaques. The examinations were 
performed by experienced sonographers. In acquiring the 
ultrasound images, each subject was lying in a comfort- 
able supine position with the head rotated 45 degrees 
away from the side of the examination. A linear array 
transducer with a minimum frequency of 7 MHz was 
manipulated at the neck region until the image demon- 
strated a transverse section of the common carotid artery 
(CCA). By moving the transducer cranially along the 
vessel to the proximal portion of internal and external 
carotid arteries (ICA & ECA), the sonographers checked 
for any stenosis, narrowing, or intimal thickening and 
performed the corresponding measurements. ICA, CCA, 
ECA and bifurcation on both left and right sides were 
examined and all the blood flow velocities at the proxi- 
mal, middle and distal portions of the CCA, and the pro- 
ximal portions of ICA and ECA were measured. A radi- 
ologist reviewed the recorded ultrasound images with 
measurements and confirmed the carotid plaque presence 
with the criterion that the discrete and focal intraluminal 
wall thickening was observed at any portion of the ca- 
rotid arteries. 
2.3. Model Evaluation Process 
This research work aimed to evaluate and compare the 
performances of the thirteen CVD risk assessment mod- 
els based on FHS, ARIC and UKPDS findings, in rela- 
tion to the presence or absence of carotid plaque as de- 
tected by ultrasound examination of an external popula- 
tion, i.e. T2DM patients in Hong Kong. 
CVD risk scores of the 49 T2DM subjects studied 
were generated by entering the collected data into each 
model. Table 2 provides a summary of the models and 
their considered risk factors. Not all the collected data 
were entered into the models. ARIC and UKPDS do not 
incorporate an option of risk factor suitable for an exter- 
nal population. For example, the options for ethnicity in 
ARIC and UKPDS do not include Chinese, and the de- 
fault of “White” was used. For those risk factors where 
the data were not collected, say menopause, atrial fibril- 
lation and Left Ventricular Hypertrophy (LVH), the de- 
fault but fixed choices were made for all the cases. Some 
risk factors were fixed due to the subject inclusion crite- 
ria of the study, e.g. smoking, diabetes, CVD and CHD. 
Every risk model generated a risk score for each sub- 
ject by entering risk factors with the collected data and 
Copyright © 2013 SciRes.                                 Openly accessible at http://www.scirp.org/journal/health/ 
L. W. C. Chan et al. / Health 5 (2013) 1-10 5
forced choices. Denote fi,j and ri as the jth risk factor and 
the risk score for the ith subject. It is assumed that there 
are (c + d) risk factors comprising of c continuous vari- 
ables and d categorical variables, based on which the risk 
score was generated. Forty-nine risk scores, r1, r2, ···, r49, 
were generated by each risk model. The predictive per- 
formances of the risk assessment models were evaluated 
by discrimination and calibration. 
2.3.1. Discrimination 
The discriminatory power of each model was assessed 
by the Area Under the Receiver-Operating Characteristic 
(AUROC) curve and its nonparametric Wilcoxon statistic 
[19]. Denote Li as the label of gold standard, which is a 
dichotomous variable, either 1 or 0, indicating the carotid 
plaque presence (case) or not (non-case) for the ith sub- 
ject, confirmed by the radiologist. The risk score ri rating 
the ith subject with the probability of CVD within certain 
period of time was combined with the gold standard label 
of carotid plaque Li to form an ordered pair (ri, Li). The 
ordered pairs for all subjects were sorted in ascending 
order of ri. A threshold value, ranging from 0 to 1, was 
set amid every two consecutive sorted ri’s to generate the 
sensitivity (true positive rate) and the 1-specificity (false 
positive rate) based on the ranking collated with the 
sorted gold standard label Li. The Receiver-Operating 
Characteristic (ROC) curve was drawn by plotting the 
sensitivity against the 1-specificity for all the threshold 
values. The empirical AUROC was computed using the 
trapezoidal rule. The Wilcoxon statistic was exploited to 
estimate the standard error (SE) of AUROC, indicating 
the sampling variability, and its asymptotic significance p, 
for the null hypothesis “true area = 0.5”. The asymptotic 
95% confidence interval (CI) was given by [AUROC − 
1.96*SE, AUROC + 1.96*SE]. The discriminatory power 
of every model was tested against the criterion that the 
empirical AUROC was significantly different from 0.5, 
implying that the model is not randomly rating the sub- 
jects. 
2.3.2. Calibration 
In the other two studies evaluating the Framingham 
scores against actual disease outcomes, the agreement 
between the predicted and actual (CVD) event rates was 
measured for non-Framingham cohort [5,10]. According 
to the risk scores generated by the risk assessment mod- 
els, the subjects were divided into deciles of the pre- 
dicted risk for a CVD event within certain period of time. 
The predicted and actual (CVD) event rates were plotted 
pair-wise for each decile to construct a bar chart for 
evaluating the calibration. 
In this study, the predicted (CVD) and actual (carotid 
plaque) outcomes are different. It is not expected to ob- 
serve the conformity between the predicted (CVD) and 
the actual (carotid plaque) event rates because the preva- 
lence of carotid plaques is obviously higher than that of 
CVD. As ‘silent’ atherosclerosis is the sub-clinical at the 
early stage of CVD, it is more meaningful to hypothesize 
the conformity between the likelihood functions of CVD 
and carotid plaque presence given a predicted risk score 
level. Trisection of risk was performed instead of form- 
ing deciles because the sample size was small. After sort- 
ing the risk scores, the subjects were divided into three 
groups: high risk, medium risk and low risk. Every sub- 
ject was graded by a particular Risk Score Range (RSR) 
and Boolean random variables: Carotid Plaque Presence 
(CPP) and Cardiovascular Disease (CVD). According to 
Bayes’ Theorem, the likelihood function of CVD given 
RSR is represented by the following formula. 
    
Pr
Pr |
Pr
RSR CVD
RSR CVD
CVD
 .        (1) 
The numerator is estimated by the sum of risk scores 
for subjects within the same range of risk and the de- 
nominator, the sum of risk scores for all subjects. The 
likelihood function of CPP given RSR is represented by 
the following formula. 
    
Pr
Pr |
Pr
RSR CPP
RSR CPP
CPP
 .       (2) 
This fraction is equivalent to the ratio of the number of 
subjects having carotid plaque and within a range of risk 
score to the number of subjects having carotid plaque. 
Instead of comparing the predicted (CVD) and actual 
(carotid plaque) event rates, the calibration in this study 
measured how closely the likelihood functions of CVD 
and CPP given a risk score range agree with each other. 
The Chi-Square χ2 statistics were employed to compare 
the differences between the two likelihood functions. 
Good calibration is indicated by small value of χ2, below 
the critical value. There is significant lack of calibration 
if the value of χ2 exceeds 20 [10]. 
3. RESULTS 
A total of 16 cases of carotid plaque were identified by 
ultrasound from the total of 49 subjects, giving a 33% 
positive rate. The AUROC analysis results of the thirteen 
original risk assessment models are shown in Table 3. 
Among the CVD risk assessment models, FHS-Lpts- 
CHD-10Y demonstrated the strongest discriminatory 
ability to differentiate those with and without carotid 
plaque, with AUROC of 0.681, in the 95% Confidence 
limits [0.524, 0.838], indicating p < 0.05. This indicates a 
non-random rating tool. The FHS-Cpts-CHD-10Y model 
ranked second with AUROC of 0.643, but this was not 
significantly different from 0.5 as the 95% Confidence 
limits were [0.479, 0.807]. The ROC curve of the FHS- 
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Table 3. AUROC for evaluating thirteen risk assessment models against the identification of carotid plaque presence in T2DM in 
Hong Kong. 
Asymptotic 
95% Confidence Interval CVD RISK MODEL AUROC Std. Errora Asymptotic Sig.b
Lower Bound Upper Bound 
(1) ARIC-Black-CHD-10Y 0.542 0.087 0.639 0.372 0.712 
(2) ARIC-White-CHD-10Y 0.545 0.087 0.609 0.375 0.716 
(3) ARIC-Black-Stroke-10Y 0.595 0.086 0.286 0.427 0.762 
(4) ARIC-White-Stroke-10Y 0.588 0.085 0.321 0.422 0.754 
(5) FHS-HCHD-10Y 0.473 0.088 0.765 0.302 0.645 
(6) FHS-Lpts-CHD-10Y 0.681 0.080 0.042c 0.524 0.838 
(7) FHS-Cpts-CHD-10Y 0.643 0.084 0.107 0.479 0.807 
(8) FHS-CHD-2Y 0.479 0.089 0.815 0.304 0.654 
(9) FHS-Stroke-10Y 0.560 0.085 0.907 0.319 0.661 
(10) UKPDS-CHD-10Y 0.513 0.091 0.881 0.335 0.692 
(11) UKPDS-Fatal-CHD-10Y 0.481 0.091 0.831 0.302 0.660 
(12) UKPDS-Stroke-10Y 0.438 0.093 0.482 0.255 0.620 
(13) UKPDS-Fatal-Stroke-10Y 0.456 0.090 0.624 0.280 0.633 
a. Under the nonparametric assumption; b. Null hypothesis: true area = 0.5; c. The significance of the AUROC of this model p < 0.05. 
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Lpts-CHD-10Y is plotted in Figure 1. When the ROC 
curve was inspected with different cutoff points of risk 
score, the empirical data confirmed at most 24% speci- 
ficity (true negative rate) at 100% sensitivity (true posi- 
tive rate). In other words, the false alarms comprised of 
76% of the sample size. The differences in AUROC be- 
tween FHS-Lpts-CHD-10Y model and the other models 
are shown in Table 4. It was found that the performance 
of FHS-Lpts-CHD-10Y model was significantly better 
than UKPDS-Stroke-10Y model only. 
To compare the likelihood function of CVD predicted 
by FHS-Lpts-CHD-10Y with the likelihood function of 
carotid plaque in different risk levels, the calibration of 
the FHS-Lpts-CHD-10Y is illustrated in Figure 2. Ac- 
cording to calibration ranking, the “low”, “medium” and 
“high” risk levels represented subjects whose predicted 
CVD risk within the ranges (0.10% - 0.42%), (0.42% - 
0.73%) and (0.73% - 1.67%) respectively. The FHS-Lpts- 
CHD-10Y underestimated the likelihood of carotid plaque 
in the “low” risk level, overestimated in the “medium” 
risk level, but well predicted carotid plaque presence in 
the “high” risk level. The Chi-Square χ2 statistic was 5.99, 
below the critical value. Thus, there was no significant 
difference between likelihood function of CVD event and 
carotid plaque presence in the three risk levels using the 
FHS-Lpts-CHD-10Y. 
Figure 1. ROC curves for evaluating the Framingham Model, 
FHS-Lpts-CHD-10Y against the identification of carotid plaque 
in T2DM in Hong Kong. 
 
FHS-Lpts-CHD-10Y model was the only model that re- 
vealed significant difference from a random scoring 
method with AUROC = 0.5 and this model outperformed 
the UKPDS-Stroke-10Y model significantly, though its 
specificity was not so satisfactory. The calibration test 
showed no significant difference between the likelihood 
of the predicted CVD and that of the actual carotid plaque 
presence in three risk levels. 
In summary, among the thirteen original CVD risk as- 
sessment models, it was found in ROC analysis that the  
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Table 4. Differences in AUROC between FHS-Lpts-CHD-10Y model and the other models. 
Asymptotic 
95% Confidence Interval Compare with 
(6) FHS-Lpts-CHD-10Y Diff. in AUROC Std. Error 
Lower Bound Upper Bound 
(1) ARIC-Black-CHD-10Y 0.139 0.118 −0.093 0.371 
(2) ARIC-White-CHD-10Y 0.136 0.118 −0.096 0.368 
(3) ARIC-Black-Stroke-10Y 0.086 0.117 −0.144 0.316 
(4) ARIC-White-Stroke-10Y 0.093 0.117 −0.136 0.322 
(5) FHS-HCHD-10Y 0.208 0.119 −0.025 0.441 
(7) FHS-Cpts-CHD-10Y 0.038 0.116 −0.189 0.265 
(8) FHS-CHD-2Y 0.202 0.120 −0.033 0.437 
(9) FHS-Stroke-10Y 0.121 0.117 −0.108 0.350 
(10) UKPDS-CHD-10Y 0.168 0.121 −0.069 0.405 
(11) UKPDS-Fatal-CHD-10Y 0.200 0.121 −0.037 0.437 
(12) UKPDS-Stroke-10Y 0.243a 0.123 0.003 0.483 
(13) UKPDS-Fatal-Stroke-10Y 0.225 0.120 −0.011 0.461 
a. The significance for the difference in AUROC between two models p < 0.05. 
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Figure 2. Likelihood function (%) of CVD event versus carotid 
plaque presence in T2DM in Hong Kong using the FHS-Lpts- 
CHD-10Y. Lpts: LDL points. Low: low risk range from 0.10% 
to 0.42%; Medium: medium risk range from 0.42% to 0.73%; 
High: high risk range from 0.73% to 1.67%. 
4. DISCUSSION 
The aims of this study were to evaluate and compare 
the discriminatory ability of thirteen CVD risk assess- 
ment models derived from the FHS, UKPDS and ARIC 
studies against the presence of carotid plaque, and to 
verify the ability for predicting the likelihood of carotid 
plaque presence using the model with the strongest dis-
criminatory ability. It was shown that the FHS-Lpts- 
CHD-10Y model can be directly applied to T2DM pa-  
tients in Hong Kong for predicting presence or absence 
of carotid atherosclerosis. The good discriminatory abil- 
ity of the FHS-Lpts-CHD-10Y can be attributed to the 
fact that it is the only model taking into account LDL-C 
as its input. Several epidemiological studies have well 
established and widely accepted the associations between 
high concentrations of LDL-C and the coronary events, 
and it was also proved that LDL-C independently pre- 
dicts coronary events in untreated patients [20]. An asso- 
ciation between LDL-C level and ischemic stroke has 
also been found in several epidemiological studies [21, 
22]. 
Further, the DBP is the input of FHS-Lpts-CHD-10Y 
and FHS-Cpts-CHD-10Y only. Though the AUROC for 
FHS-Cpts-CHD-10Y was not significantly different from 
0.5, it ranked the second among all the evaluated models. 
It was shown in a retrospective study that the prevalence 
of diastolic abnormalities, such as high DBP, in the sub- 
ject group with carotid intimal-medial thickness (CIMT) 
greater than 1mm was significantly higher than that with 
carotid IMT < 1 mm [23]. The permanent increase in 
blood pressure leads to an increase in arterial stiffness 
due to the adaptive structural alteration of arterial wall 
with elevated collagen compound [24]. It also recom- 
mended further investigation into the interactive effect of 
LDL-C and DBP on the atherosclerosis. 
The calibration test demonstrated the performance of 
the FHS-Lpts-CHD-10Y in the stratified risk score levels: 
high, medium and low risk ranges. Given the same risk 
level, the likelihood of predicted CVD agreed with the 
Copyright © 2013 SciRes.                                 Openly accessible at http://www.scirp.org/journal/health/ 
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likelihood of actual carotid plaque presence. This finding 
confirmed the effectiveness of this model in classifying 
the patients into three different risk levels, which might 
improve the prognostic stratification of T2DM patients 
and help recognize the subset of patients at high risk of 
atherosclerosis early. 
The highest predication accuracy attained in this study 
was indicated by AUROC = 0.681. Though this model 
was not a random rating tool, the attained accuracy lying 
between 0.5 and 0.7 was marginally acceptable. When it 
was considered as a screening tool, the trade-off in false 
alarms (76%) was unavoidable for achieving zero miss- 
ing case. There clearly exists room for further improve- 
ment. Firstly, the newly emerging biomarkers, such as 
hs-CRP, plasma ascorbic acid (AA), uric acid, triglyc- 
erides and homocysteine, have not been incorporated 
into the models. A review paper emphasized that hs-CRP 
independently predicts future CVD events and provides 
additional prognostic information to lipid screening, 
metabolic disorder (e.g. diabetes) and FHS risk score 
[25]. Clinical and epidemiological studies also provided 
evidence that hs-CRP, as an inflammatory marker, plays 
a very important role in the pathogenetic mechanism in 
atherosclerosis [26]. As LDL oxidation is critical in the 
progression of atherosclerosis, the atherosclerosis sup- 
pressing effect of plasma AA inhibits the LDL oxidation 
by acting as a pro-oxidant in the presence of metal ions 
and scavenging the free radicals, such as hydroperoxides 
[27]. It was also shown that plasma AA in atheromatous 
aortas is less concentrated than in control blood vessels 
and the concentration of plasma AA in healthy subjects is 
inversely correlated with the mortality of CHD in follow- 
up [28-30]. Therefore, it is expected that more precise 
prediction of atherosclerosis can be achieved by com- 
bining the FHS-Lpts-CHD-10Y with the effect of the 
newly emerging biomarkers to generate a global risk 
score. Further study will investigate the value of their 
integration into an atherosclerotic risk assessment model, 
which adopts the FHS-Lpts-CHD-10Y as its basic com- 
ponent and is able to expand infinitely with the risk 
mappings of the newly emerging biomarkers. 
5. CONCLUSION 
In predicting the presence of carotid plaque, the FHS- 
Lpts-CHD-10Y outperformed the other 12 CVD risk 
assessment models that have been derived from the FHS, 
UKPDS and ARIC. The FHS-Cpts-CHD-10Y ranked 
next, but its performance was not significantly different 
from a random scoring approach. The calibration perfor- 
mance suggested that the FHS-Lpts-CHD-10Y model 
provides three-level atherosclerotic risk stratification for 
easy identification of high risk patients. The findings of 
this study encourage the establishment of an integrated 
atherosclerotic risk assessment model, which employs 
the FHS-Lpts-CHD-10Y as its basic component, but with 
the added value of newly emerging biomarkers, such as 
hs-CRP, plasma AA, uric acid, triglycerides and homo- 
cysteine, as the additional components. In future research 
work, this integrated model will be validated and refined 
using the data collected in this research so as to achieve 
much larger AUROC and smaller false positive rate at 
100%-sensitivity cutoff point, enabling targeted preven- 
tive care to high risk individuals. 
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